We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Advisory Committee Splits on COPD Indication for GlaxoSmithKline Drug
FDA Advisory Committee Splits on COPD Indication for GlaxoSmithKline Drug
An advisory panel Wednesday recommended that the FDA collect more data before signing off on use of GlaxoSmithKline’s asthma drug mepolizumab for treating chronic obstructive pulmonary disease (COPD).